PMID: 9450804Feb 5, 1998Paper

Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression

British Journal of Haematology
O LegrandR Zittoun

Abstract

Biphenotypic acute leukaemia (BAL) patients represented 8% of the 287 de novo consecutive adult acute leukaemias (23 BAL, 230 acute myeloid leukaemia (AML) and 34 acute lymphoblastic leukaemia (ALL)) referred to our department during the last 4-year period. Of these 23 BAL patients, 14 patients showed myeloid morphology and nine cases lymphoid morphology according to FAB criteria. There were no differences between lymphoid and myeloid BAL according to clinical and biological presentation and treatment outcome. We confirm the poor prognosis of BAL when compared to AML or ALL seen during the same period of time, in terms of complete remission (47%, 62% and 82% respectively, BAL v AML, NS and BAL v ALL, P = 0.006) and 4-year overall survival (8.1%, 25.8% and 23.8% respectively, BAL v AML, P = 0.05 and BAL v ALL, P = 0.003). Comparing adult BAL patients with AML patients, we found an increase in poor prognostic factors: CD34+ phenotype (82% v 60% respectively, P = 0.03), unfavourable karyotype (60% v 20%, P < 0.0001) and Pgp over-expression by RT-PCR (0.705 v 0.107, P < 0.0001) and flow cytometry (0.824 v 0.391, P = 0.0001). MRP and LRP were not found to be poor prognostic factors. Comparing BAL patients with ALL patients, we found...Continue Reading

References

Jul 1, 1977·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·I T Young
Jul 1, 1991·British Journal of Haematology·J M BennettC Sultan
Feb 1, 1991·Annals of Hematology·D CatovskyR Morilla
Jan 1, 1991·Leukemia Research·R SasakiF Takaku
Jun 1, 1990·British Journal of Haematology·A Urbano-IspizuaC Rozman
Dec 1, 1989·British Journal of Haematology·F Lo CocoF Mandelli
Apr 30, 1987·The New England Journal of Medicine·R E SobolD A Nelson
Mar 1, 1987·British Journal of Haematology·R P Gale, I Ben Bassat
Jun 1, 1995·Nature Medicine·G L SchefferR J Scheper
Jun 1, 1995·Pflügers Archiv : European journal of physiology·C De GreefB Nilius
May 1, 1993·British Journal of Haematology·C A HansonL M Stoolman
Aug 30, 1994·International Journal of Radiation Oncology, Biology, Physics·N F MivechiG M Hahn
Jan 1, 1993·Leukemia & Lymphoma·V Gandhi
Sep 1, 1993·Cancer Genetics and Cytogenetics·M WoodL M Secker-Walker
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P MarieR Zittoun

❮ Previous
Next ❯

Citations

Feb 16, 2013·Annals of Hematology·Sandra HeeschClaudia D Baldus
Feb 22, 2008·International Journal of Hematology·Guangsheng HeChanggeng Ruan
May 6, 1999·Leukemia Research·J F NomdedéuE Rubiol
Nov 1, 2003·Best Practice & Research. Clinical Haematology·Richard SchabathWolf Dieter Ludwig
Apr 23, 2003·The Journal of Molecular Diagnostics : JMD·Amgad L NashedMargaret L Gulley
May 21, 2010·Leukemia·W van den AnckerA A van de Loosdrecht
Feb 15, 2002·Clinical and Laboratory Haematology·B J BainUNKNOWN General Haematology Task Force of the British Committee for Standards in Haematology (BCSH), British Society of Haematology
Aug 28, 2002·Reviews in Clinical and Experimental Hematology·Robin Foa, Antonella Vitale
May 2, 2002·Journal of Hematotherapy & Stem Cell Research·Alexander A Shtil
Nov 16, 2004·International Journal of Hematology·Masahiro OnozawaMasahiro Asaka
Aug 29, 2009·Haematologica·Amal S Al-SeraihyAsim F Belgaumi
Oct 23, 2013·Annals of Hematology·Marcela Deffis-CourtErick Crespo-Solís
Aug 16, 2012·Leukemia & Lymphoma·Olga Frankfurt, Leonidas C Platanias
Aug 10, 1999·Leukemia & Lymphoma·M P ScolnikM M Bracco
Apr 10, 2008·Leukemia & Lymphoma·Je-Hwan LeeUNKNOWN Korean Society of Hematology AML/MDS Working Party
Nov 19, 2011·Hematology/oncology Clinics of North America·David P Steensma
Nov 21, 2009·American Journal of Clinical Pathology·Adam C SeegmillerRobert W McKenna
Dec 23, 2008·Cancer Genetics and Cytogenetics·Tae Sung ParkJong Rak Choi
Mar 21, 2007·American Journal of Clinical Pathology·Xin Han, Carlos E Bueso-Ramos
May 22, 2007·Leukemia Research·Yesid AlvaradoFrancis J Giles
Jun 3, 2009·Pediatric Blood & Cancer·Jeong A ParkJong Jin Seo
Jun 8, 2004·British Journal of Haematology·Mario TiribelliRenato Fanin
Nov 25, 2003·British Journal of Haematology·M T RubioJ P Vernant
Aug 18, 2012·Asia-Pacific Journal of Clinical Oncology·Haixia TongQiushi Wang
Mar 10, 2011·British Journal of Haematology·Gert J OssenkoppeleGerrit Jan Schuurhuis
Jul 31, 2013·British Journal of Haematology·Kalliopi N Manola
Apr 23, 2014·European Journal of Haematology·Hiroaki ShimizuYoshihisa Nojima
Jan 21, 2010·British Journal of Haematology·Heidrun GerrDirk Reinhardt
Jan 22, 2015·Blood·Ofir Wolach, Richard M Stone

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.